Welcome to DU! The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards. Join the community: Create a free account Support DU (and get rid of ads!): Become a Star Member Latest Breaking News Editorials & Other Articles General Discussion The DU Lounge All Forums Issue Forums Culture Forums Alliance Forums Region Forums Support Forums Help & Search

douglas9

(5,714 posts)
Wed Feb 18, 2026, 01:25 PM 14 hrs ago

FDA agrees to review Moderna mRNA flu vaccine in dramatic reversal

The U.S. Food and Drug Administration will review a messenger RNA (mRNA) flu vaccine for approval, according to its maker, Moderna. The decision is a dramatic U-turn for the agency, which, only about a week ago, had publicly rejected Moderna’s application to get the shot reviewed.

When it initially rejected the application, the FDA had said Moderna’s clinical trials were lacking. On Wednesday, Moderna said it had made modifications to its application. While the reversal has been welcomed by the vaccine maker and public health experts alike, the incident has been the latest instance of the Trump administration undermining vaccine science. Secretary of Health and Human Services Robert F. Kennedy, Jr., whose department has jurisdiction over the FDA, is a noted vaccine skeptic who has repeatedly criticized mRNA COVID vaccines.

HHS spokesperson Andrew Nixon said in a statement that the FDA had held discussions with the company, leading to “a revised regulatory approach and an amended application, which FDA accepted.”

“FDA will maintain its high standards during review and potential licensure stages as it does with all products,” Nixon said.

William Schaffner, an infectious disease physician and a professor at Vanderbilt University Medical Center, says the FDA’s decision to backtrack is “good news.”

https://www.scientificamerican.com/article/fda-agrees-to-review-moderna-mrna-flu-vaccine-in-dramatic-reversal/

2 replies = new reply since forum marked as read
Highlight: NoneDon't highlight anything 5 newestHighlight 5 most recent replies
FDA agrees to review Moderna mRNA flu vaccine in dramatic reversal (Original Post) douglas9 14 hrs ago OP
They probably have to gift a solid gold flu virus statue to tRump to make it happen. nt yaesu 14 hrs ago #1
FDA reverses course, will review Moderna's mRNA flu vaccine LetMyPeopleVote 13 hrs ago #2

yaesu

(9,160 posts)
1. They probably have to gift a solid gold flu virus statue to tRump to make it happen. nt
Wed Feb 18, 2026, 01:32 PM
14 hrs ago

LetMyPeopleVote

(177,433 posts)
2. FDA reverses course, will review Moderna's mRNA flu vaccine
Wed Feb 18, 2026, 02:43 PM
13 hrs ago

Moderna revised its application following the FDA's surprise decision to not review the flu shot.

A bit of good news this morning: FDA reverses course, will review Moderna's mRNA flu vaccine

www.nbcnews.com/health/healt...

Laura Haynes👩‍🔬⚾️🐾💙 (@drlaurahaynes.bsky.social) 2026-02-18T14:13:46.545Z

https://www.nbcnews.com/health/health-news/fda-reverses-course-will-review-modernas-mrna-flu-vaccine-rcna259531

Moderna said on Wednesday the U.S. Food and Drug Administration has agreed to review its influenza vaccine, reversing an earlier decision to reject the application, after the company made modifications.

The reversal, which comes just a week after the FDA’s surprise decision to not review the company’s experimental flu vaccine application, lifted shares of the vaccine maker more than 3% before the bell.

The FDA has accepted Moderna’s revised approach seeking full approval for the shot for adults aged between 50 and 64, and accelerated approval for those aged 65 and above, the company said, adding that it will also conduct a post-marketing study in older adults.

The mRNA technology used in Moderna’s and most other Covid shots, credited with saving millions of lives, comes with a shift in the national health policy under Health Secretary Robert F. Kennedy Jr., a long-time anti-vaccine activist who has been particularly critical of mRNA vaccines.

The regulator had defended its initial decision, saying the company should have given a higher-strength vaccine to older patients in the control arm of its trial.

Latest Discussions»Issue Forums»Health»FDA agrees to review Mode...